

## Kişisel Bilgiler

E-posta: serkan.akin@hacettepe.edu.tr

## Araştırma Alanları

Onkoloji

## SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement**  
Kupik O., Akin S., Tuncel M., Eren G., Türker A., Kars A., Erbaş B.  
NUCLEAR MEDICINE COMMUNICATIONS, cilt.41, sa.6, ss.540-549, 2020 (SCI İndekslerine Giren Dergi)
- II. **Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx ) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience**  
Acar R., Ertürk I., Kiziloz H., Okcelik S., Yıldız B., Aykan M. B. , Keskin G. S. Y. , Buyukturan G., AKIN S., Karadurmuş N.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.30, sa.4, ss.191-196, 2020 (SCI İndekslerine Giren Dergi)
- III. **Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study**  
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C. , ARIK Z., Ates O., Yılmaz M., Meydanlı M. M. , Oksuzoglu B.  
JOURNAL OF BUON, cilt.24, sa.6, ss.2327-2332, 2019 (SCI İndekslerine Giren Dergi)
- IV. **Association between androgen receptor status and prognosis in triple negative breast cancer**  
Sunar V., Dogan H. T. , Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., AKSOY S., Altundag K.  
JOURNAL OF BUON, cilt.23, sa.5, ss.1325-1330, 2018 (SCI İndekslerine Giren Dergi)
- V. **Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma**  
AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.  
CURRENT PROBLEMS IN CANCER, cilt.42, sa.3, ss.344-349, 2018 (SCI İndekslerine Giren Dergi)
- VI. **Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms**  
AKIN S., DİZDAR Ö., Hayran M.  
ANNALS OF SURGICAL ONCOLOGY, cilt.24, 2017 (SCI İndekslerine Giren Dergi)
- VII. **Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database**  
DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.  
JOURNAL OF BUON, cilt.22, sa.2, ss.530-534, 2017 (SCI İndekslerine Giren Dergi)
- VIII. **Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma**  
Akin S., Aksoy D. Y. , AKIN S., KILIÇ M., Yetisir F., BAYRAKTAR M.  
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.47, sa.6, ss.1723-1727, 2017 (SCI İndekslerine Giren Dergi)
- IX. **Left laterality is an independent prognostic factor for metastasis in N3 stage breast cancer**  
Karatas F., Sahin S., Erdem G. U. , ATEŞ Ö., BABACAN T., AKIN S., SEVER A. R. , Ozisik Y., Altundag K.  
JOURNAL OF BUON, cilt.21, sa.4, ss.851-858, 2016 (SCI İndekslerine Giren Dergi)
- X. **Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients**  
Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R. , AKIN S., Ozisik Y., Altundag K.  
JOURNAL OF BUON, cilt.21, sa.4, ss.799-808, 2016 (SCI İndekslerine Giren Dergi)
- XI. **Correlation of educational status and clinicopathological characteristics of breast cancer: a single**

**center experience**

Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R. , KERTMEN N., Unlu O., ATEŞ Ö., DIKER O., AKIN S., et al.

JOURNAL OF BUON, cilt.21, sa.4, ss.826-831, 2016 (SCI İndekslerine Giren Dergi)

- XII. **Interpretation of survival data: which graphical analysis is appropriate?**  
Dizdar O., AKIN S., HAYRAN M.  
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, cilt.8, sa.4, ss.312, 2016 (SCI İndekslerine Giren Dergi)
- XIII. **Analysis of the Adjuvant Hormone Therapy Randomized Trial**  
Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.  
JOURNAL OF CLINICAL ONCOLOGY, cilt.34, sa.17, ss.2070-2071, 2016 (SCI İndekslerine Giren Dergi)
- XIV. **Leg cramps associated with tamoxifen use - possible mechanism and treatment recommendations**  
Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R. , Altundag K.  
JOURNAL OF BUON, cilt.21, sa.2, ss.520, 2016 (SCI İndekslerine Giren Dergi)
- XV. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**  
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., Karakas Y., KILIÇKAP S., Ozisik Y., SEVER A. R. , et al.  
JOURNAL OF BUON, cilt.21, sa.2, ss.375-381, 2016 (SCI İndekslerine Giren Dergi)
- XVI. **Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy**  
AKIN S., DİZDAR Ö., ÖZİŞİK L., TANRIOVER M. D. , KAMISLI S., ERMAN M., HAYRAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.26, sa.3, ss.167-172, 2016 (SCI İndekslerine Giren Dergi)
- XVII. **Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer**  
Karatas F., Sahin S., BABACAN T., AKIN S., SEVER A. R. , Altundag K.  
JOURNAL OF BUON, cilt.20, sa.6, ss.1640, 2015 (SCI İndekslerine Giren Dergi)
- XVIII. **Does eribulin mesylate cause recurrent transient diplopia?**  
Karatas F., Hacıoglu B., AKIN S., BABACAN T., SEVER A. R. , Altundag K.  
JOURNAL OF BUON, cilt.20, sa.5, ss.1379, 2015 (SCI İndekslerine Giren Dergi)
- XIX. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer**  
BABACAN T., Efe O., Hasirci A. S. , Demirci F., Buyukhatipoglu H., Balakan O., Sarici F., KERTMEN N., Esin E., AKIN S., et al.  
TUMORI J, cilt.101, sa.4, ss.418-423, 2015 (SCI İndekslerine Giren Dergi)
- XX. **Can aromatase inhibitors cause forgetfulness in women with breast cancer ?**  
Karatas F., AKIN S., BABACAN T., SEVER A. R. , Altundag K.  
JOURNAL OF BUON, cilt.20, sa.3, ss.935, 2015 (SCI İndekslerine Giren Dergi)
- XXI. **Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis**  
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., AKIN S., ATEŞ Ö., Karakas Y., Aslan A., et al.  
JOURNAL OF BUON, cilt.20, sa.2, ss.479-486, 2015 (SCI İndekslerine Giren Dergi)
- XXII. **How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?**  
Hacıoglu B., AKIN S., BABACAN T., SEVER A. R. , Altundag K.  
FUTURE ONCOLOGY, cilt.11, sa.20, ss.2799-2801, 2015 (SCI İndekslerine Giren Dergi)
- XXIII. **Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab**  
ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.  
JOURNAL OF BUON, cilt.20, sa.1, ss.349, 2015 (SCI İndekslerine Giren Dergi)
- XXIV. **Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients**  
Hacıoglu B., AKIN S., SEVER A. R. , Altundag K.

- FUTURE ONCOLOGY, cilt.11, sa.18, ss.2495-2497, 2015 (SCI İndekslerine Giren Dergi)
- XXV. **Comparison of three different induction regimens for nasopharyngeal cancer**  
KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., Sarici F., AKIN S., Altundag K., Gullu H. I.  
Asian Pacific Journal of Cancer Prevention, cilt.16, sa.1, ss.59-63, 2015 (SCI Expanded İndekslerine Giren Dergi)
- XXVI. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**  
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.  
JOURNAL OF BUON, cilt.20, sa.1, ss.35-39, 2015 (SCI İndekslerine Giren Dergi)
- XXVII. **Acute erythroid leukemia in a patient with chronic lymphocytic leukemia**  
GÜVEN D. C. , BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.  
JOURNAL OF BUON, cilt.19, sa.4, ss.1127, 2014 (SCI İndekslerine Giren Dergi)
- XXVIII. **Breast sarcoma: A rare malignancy**  
Gul G., BABACAN T., AKIN S., Sarici F., Altundag K.  
JOURNAL OF BUON, cilt.19, sa.2, ss.577, 2014 (SCI İndekslerine Giren Dergi)
- XXIX. **A novel targeted therapy in breast cancer: Cyclin dependent kinase inhibitors**  
AKIN S., BABACAN T., Sarici F., Altundag K.  
JOURNAL OF BUON, cilt.19, sa.1, ss.42-46, 2014 (SCI İndekslerine Giren Dergi)
- XXX. **Nasopharyngeal sarcoidosis: a rare involvement**  
Akin S., Akin S., KARADAĞ Ö., KALYONCU U., Balci S., ÖZGEN MOCAN B.  
RHEUMATOLOGY INTERNATIONAL, cilt.32, sa.5, ss.1407-1409, 2012 (SCI İndekslerine Giren Dergi)
- XXXI. **Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature**  
Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C. , Akin S., SAYINALP N., HAZNEDAROĞLU İ. C. , ÖZCEBE O. İ.  
MEDICAL ONCOLOGY, cilt.27, sa.1, ss.55-58, 2010 (SCI İndekslerine Giren Dergi)

## **Diğer Dergilerde Yayınlanan Makaleler**

- I. **Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları**  
AKIN S., AKIN Ş., Karaağaç A. T. , HAZNEDAROĞLU İ. C.  
Journal of Contemporary Medicine, cilt.7, sa.4, ss.316-322, 2017 (Diğer Kurumların Hakemli Dergileri)
- II. **Symptomatic Adrenal Insufficiency due to Bilateral Adrenal Non-Hodgkin's Lymphoma**  
AKIN Ş., Akin S., TUNCEL M., ERSÖZ G. N.  
Turkish Journal of Endocrinology and Metabolism, cilt.20, ss.108-110, 2016 (Diğer Kurumların Hakemli Dergileri)

## **Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar**

- I. **The Role of FDG PET/CT Detecting Bone Marrow Involvement in Non-Hodgkin's Lymphoma Patients**  
KUPIK O., Akin S., TUNCEL M., TÜRKER A., Kars A., Erbas B.  
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Almanya, 13 - 17 Ekim 2018, cilt.45
- II. **The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.**  
Karakas Y., Dizdar O., Akin S., Ates O., Sendur M. A. N. , Aksoy S., Hayran M., Gullu I. H. , Ozisik Y. Y. , Altundag K.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- III. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**  
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akin S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y. , et al.  
ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015
- IV. **Signet ring cell carcinoma of breast: Single center experience.**

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

**V. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**

Altundag K., Babacan T., Efe O., Hasirci A. S. , Demirci F., Buyukhatipoglu H., Balakan O., Sarici F. S. , Kertmen N., Esin E., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

**VI. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.**

Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R. , Unlu O., Ates O., Sarici S. F. , Akin S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

**VII. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.**

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F. , Akin S., Altundag K., Gullu I. H.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

**VIII. Is there any correlation between molecular subtypes and blood groups in breast cancer?**

Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F. , Keskin G. S. Y. , Diker O., Akin S., Altundag O., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

**IX. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F. , Sendur M. A. N. , Arik Z., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32

## Atıflar

Toplam Atıf Sayısı (WOS):96

h-indeksi (WOS):6